AVX 13616 - CAS 900814-48-4

AVX 13616, Avexa's leading antibacterial candidate, demonstrates significant in vivo antibacterial efficacy, especially against drug-resistant Staphylococcus pathogens, with an IC50 value of 2-4 μg/ml (MICs) and is targeted as an antibacterial agent. Comparable in activity to mupirocin within a nasal decolonization model, AVX13616 necessitated only a single application for effectiveness. This compound, alongside others, exhibited broad-spectrum antibacterial action, achieving MICs of 2-4 micrograms per milliliter against various isolates, including S. aureus, coagulase-negative staphylococci, enterococci, MRSA, VISA, and VRSA. Aimed for topical use and the treatment of wound infection or catheter-related infections, a solitary 5% (w/w) AVX13616 application (roughly equivalent to 2% mupirocin) proved as efficacious as twice-daily 2% mupirocin over five days in decolonizing MRSA in mice.

Others, Antibacterial

Microbiology/Virology, Others

900762

C50H73Cl2N7O7

955.08

O=C(C(CC(C)C)NC(C(CCCNC(N)=N)NC(C(CCCCN)NC(COC1=C(C2=C(C=CC3=C2C=CC=C3)OCCC(C)C)C4=C(C=CC=C4)C=C1)=O)=O)=O)OCCC(C)C.Cl.Cl

-20°C

Ice Packs

Small Compound